Molecular Oncology Program 1120 15th Street CB 2503 Augusta, GA 30912 Office: (706) 721-6143 E-mail:

Li, Honglin, Ph.D.

Dr. Honglin Li

Li, Honglin, Ph.D.
Member, Tumor Signaling and Angiogenesis

Associate Professor, Graduate Studies
Associate Professor,  Department of Biochemistry and Molecular Biology

GRU Cancer Center


1120 15th Street
Augusta, GA 30912
Office: (706) 721-6143

IFL Link | PubMed Link


Professional Overview

Dr. Li is an associate professor in the Department of Biochemistry and Molecular Biology and a member of the Cancer Center at Georgia Regents University.  He received his B.Sc from University of Sciences and Technology of China (1988) and Ph.D. from Wayne State University, Detroit, MI (1994).


Current Research

Dr. Li studies the roles of the newly identified C53/RCAD protein complex in normal animal development and cancers.  The C53/RCAD protein complex has been recently shown by the Li laboratory and others to function as a pivotal regulator of multiple cell signaling pathways, including the DNA damage response, NF-kB signaling and cell cycle progression.  Its role in tumorigenesis and metastasis has also been investigated in head and neck carcinomas and hepatocarcinomas, yet its biological function and the underlying molecular mechanisms remain elusive.  The Li laboratory has been studying this novel complex using various techniques including knockout mice, gene profiling and proteomics.  Their recent findings suggest that this protein complex is essential for maintaining stem cell pluripotency and fate determination in early embryonic development.  In addition, the Li laboratory found that the C53/RCAD complex is highly expressed in large cell lung cancers, and depletion of these proteins leads to reduced proliferation, migration and invasion of lung cancer cells.  Their findings may facilitate the development of a novel diagnostic biomarker and therapeutic target for lung cancer treatment.

 Publications (selected):

Li, H. and Nicholson, A. W. (1996) Defining the enzyme binding domain of a ribonuclease III processing signal. Ethylation interference and hydroxyl radical footprinting using catalytically inactive RNase III mutants. EMBO J. 15, 1421-1433.

Li, H., Bergeron, L., Cryns, V., Pasternack, M. S., Zhu, H., Shi, L., Greenberg, A., Yuan, J. (1997) Activation of caspase-2 in apoptosis. J. Biol. Chem. 272, 21010-21017.

Zhou, B-B., Li, H., Yuan, J., Kirschner, M. W. (1998) Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc. Natl. Acad. Sci. USA 95, 6786-6790.

Li, H., Zhu, H., Xu, C., Yuan, J. (1998) Cleavage of BID by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell94, 491-501.

Chou, J. J., Li, H., Salvesen, G., Yuan, J. and Wagner, G. (1999) Solution structure of Bid, an intracellular amplifier of apoptotic signaling. Cell 96, 615-624

Li, H. and Yuan, J. (1999) Deciphering the pathways of life and death. Current Opinion in Cell Biology 11, 261-266.

Tong, X. and Li, H. (2004) eNOS protects from prostate cancer cells from TRAIL-induced apoptosis. Cancer Letters 210, 63-71.

Wu, J., Luo, S., Hai, J., Li, H. (2005) Mammalian CHORD-containing protein 1 is a novel heat shock protein 90-interacting protein. FEBS letters 579, 421-426.

Jiang, H., Luo, S., Li, H. (2005) Cdk5 activator binding protein C53 regulates apoptosis induced by genotoxic stress via modulating cyclin B1 phosphorylation. J. Biol. Chem. 280, 20651-20659


Yang, W., Monroe, J. Zhang, Y., George, D., Bremer, E, Li, H. (2006) Proteasome inhibition induces both pro-and anti-cell death pathways in prostate cancer cells. Cancer Letters 243, 217-227.

Jiang, H., Wu, J., He, C., Yang, W., Li, H. (2009) A tumor suppressor C53 protein antagonizes checkpoint kinases to promote cyclin-dependent kinase 1 activation. Cell Research 19, 458-468.

Wu, J., Lei, G., Mei, M, Li, H. (2010) A novel C53/LZAP-interacting protein regulates C53/LZAP stability and NF-kB signaling. J. Biol. Chem. 285, 15126-15136.

Zhu, S., Zhang, J., Bai, G., Li, H. (2011) Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington’s disease. Cell Death and Diseases 2 (in press).